Abstract. Fibrolamellar hepatocellular carcinoma (FL-HCC) is a variant of hepatocellular carcinoma (HCC) that most commonly affects adolescents and young adults and is associated with an extremely poor prognosis due to the lack of effective chemotherapeutic agents. Mutations in p53 are a common oncogenic driver in HCC but not in FL-HCC. However, in tumors lacking a p53 mutation, the tumor suppressor activity of p53 has been revealed to be dysregulated in several different cancer types. One mechanism has been attributed to the overexpression of mouse double minute 4 protein (MDM4), a negative regulator of p53, which inhibits the normal functions of p53 including induction of apoptosis and DNA repair. Therefore, restoring the normal function of p53 in cancer cells by targeting MDM4 has become a potential therapeutic strategy. Hence, in the present study the components of the DNA damage response (DDR) pathway were examined; ATM, p53, and MDM4 in FL-HCC. Seven FL-HCC tumors along with their adjacent non-neoplastic hepatic tissues were examined. Ataxia-telangiectasia mutated (ATM), p53, and MDM4 protein expression was assessed using western blot analysis and cellular localization was determined using immunohistochemistry (IHC). MDM4 mRNA transcript levels were assessed using RT-qPCR. The present results demonstrated that the DNA damage sensor, ATM, is phosphorylated and localized to the nuclei of tumor cells. While there was a significant increase in total p53 protein in tumor cells, phosphorylated p53 was revealed to preferentially localize to the cytoplasmic compartment of tumor cells. Notably, the present results revealed that MDM4 transcript levels were increased in the majority of tumor samples and the nuclear MDM4 levels were significantly increased in tumor tissue compared to their adjacent non-neoplastic liver tissue. The present results indicated that increased MDM4 expression and nuclear localization may be a potential mechanism for p53 dysregulation in FL-HCC.

Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide (1). Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare subtype of HCC, which typically occurs in adolescents and young adults (2-4). FL-HCC has unique histological characteristics such as large, polygonal tumor cells with eosinophilic or oncocytic cytoplasm, large nuclei with prominent single nucleolus, and pericellular lamellar collagen fibrosis (5,6) that sets it apart from conventional HCC. In addition, patients with FL-HCC generally do not have underlying liver disease (7) as opposed to conventional HCC which is commonly associated with cirrhosis and/or chronic viral hepatitis (8). Surgical resection is the predominant mode of treatment for FL-HCC and provides the only chance at a cure (9). However, the mortality rates remain high as a significant percentage of patients present with advanced or unresectable disease. Even patients who undergo surgical resection have a high risk of tumor recurrence. Therefore, overall survival of patients with FL-HCC will continue to be poor until effective chemotherapeutic agents are identified.

A recent approach to treating cancers has focused on activating the tumor suppressor function of p53, known as the ‘guardian of the genome’ (10,11), which under normal conditions undergoes activation once there is DNA damage or instability (12). Ataxia-telangiectasia mutated (ATM), is a serine/threonine kinase that is often initially activated upon DNA damage (13,14) and subsequently signals p53 to perform DNA repair, inhibit abnormal cell growth, or induce apoptosis (15-18). Conversely, p53 activity may be negatively regulated by mouse double minute 2 homolog (MDM2) or mouse double minute 4, human homolog (MDM4) (19). MDM2, an E3 ubiquitin-protein ligase, leads to the degradation of p53 through the proteasomal pathway and MDM4 exerts its inhibitory activity via binding to p53 transactivation domain (20-23).

Approximately 50% of all human cancers contain p53 mutations, which in turn results in the loss of p53 tumor suppressor function leading to cancer initiation and progression (24). There is now increasing evidence that even in cancers with non-mutated p53, the function of p53 is altered such that it...
favors the biology of the cancer cell and prevents the apoptosis of the transformed cell. One mechanism responsible for the dysregulation of p53 function has been attributed to the inhibitory effect of MDM4 (25,26). The overexpression of MDM4 has been reported in various cancer types with non-mutated p53 (27). For example, MDM4 expression is elevated in 65% of human melanomas and in an animal model with Nras oncogene activation; overexpression of MDM4 increased cancer promotion in melanocytes (28). Similarly, in vitro studies of breast cancer lacking p53 mutations demonstrated that MDM4 knockdown inhibited cell growth (29). Collectively, these studies indicated that overexpression of MDM4 may result in dysregulation of p53 function and inhibition of MDM4 may provide a therapeutic approach for treating cancers that lack p53 mutations.

As opposed to conventional HCC, which is commonly associated with mutations in p53 (8,30), FL-HCC is not linked to any p53 mutations (24,31,32), however, there is evidence for p53 pathway dysregulation based on transcriptome analysis of FL-HCC (33). Additionally, studies have reported that conventional HCC tumors lacking p53 mutations have increased MDM4 expression indicating that p53 function is disrupted (1,31,34,35). Thus, in the present study, it was examined whether this tumor type is also associated with p53 dysregulation by examining the DDR components; ATM, p53, and MDM4.

Materials and methods

Tumor samples. Seven FL-HCC tumor samples and their matched non-neoplastic liver samples were obtained from patients who underwent hepatic resection or liver transplantation under an approved protocol by the Institutional Review Board (IRB) at Boston Children's Hospital. Written informed consent was obtained from the parents of patients under 18 years of age. The neoplastic and non-neoplastic tissues were reviewed by an expert liver pathologist (ARPA).

Histology and immunohistochemistry. Samples were fixed, embedded in paraffin, sectioned, and stained using conventional histological techniques by the Core Histology Facility at Boston Children's Hospital. Hematoxylin and eosin (H&E) staining was performed on 4-µm tissue sections as previously reported by LaQuaglia et al (36). Briefly, the paraffin slides were dehydrated for 60 sec in methanol, followed by 120 sec staining in Harris' Hematoxylin (Sigma Aldrich; Merck KGaA). The slides were washed in water for 20 sec. Next, the slides were incubated in the bluing reagent for 60 sec (Thermo Fisher Scientific, Inc.) and transferred onto PVDF membranes using Trans-Blot Turbo Transfer System (both from Bio-Rad Laboratories, Inc.). Membranes were subjected to blocking for 2 h at room temperature in 5% non-fat dry milk in tris-buffered saline and 0.1% Tween-20. Immunoblot membranes were incubated in primary antibodies at 4°C overnight against the antibodies: MDM4 (Abgent, Inc.; cat. no. ALS13152, dilution:1:1,000), p53 (Abcam; cat. no. PAb1801, dilution:1:1,000), phospho p53-S15 (Cell Signaling Technologies, Inc., cat. no. 9284S; dilution: 1:1,000), PKA (Santa Cruz Biotechnology, Inc., cat. no. sc-903; dilution: 1:1,000), α-tubulin (GeneTex, Inc.; cat. no. GTX628802; dilution:1:3,000), GAPDH (Cell Signaling Technologies, Inc., cat. no. 97166; dilution:1:3,000 and GenTex, Inc., cat. no. GTX627408; dilution:1:3,000) and β-actin (Cell Signaling Technologies, Inc.; cat. no. 4970S; dilution:1:3,000). This was followed by three 10-min washes. Membranes were then incubated in horseradish peroxidase (HRP) conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, INC, anti-mouse- cat. no. 205-005-108; dilution:1:5,000, anti-rabbit; cat. no. 111-035-144; dilution:1:5,000) at room temperature for 45 min followed by three washes with TBST. Immunoblots were visualized using an enhanced chemiluminescence (ECL) kit (Bio-Rad Laboratories, Inc. and Thermo Fisher Scientific, Inc.). We did not have ample tumor tissue from patient P6 to perform all of the western blot analyses. Protein quantification was performed using ImageJ software version:1.48v (National Institutes of Health) (normalized to GAPDH or β-actin). GraphPad Prism 7 (GraphPad Software) was used to generate graphs and Mann Whitney U test was used to generate P-values.

RNA expression analysis. Total cellular RNA from tumor and non-neoplastic liver samples was extracted using the E.Z.N.A midi kit (Qigen, Inc.). One microgram of RNA was subjected to reverse transcription using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Inc.). Gene amplification was performed using SYBR Rox and an AB 7000 Real-Time PCR system. Thermocycling conditions used were: 37 cycles...
at 95°C for 30 sec, 59°C for 1 min, and 72°C for 30 sec with the following primers MDM4 (Hs00910358_s1) and GAPDH (Hs02758991_g1) (all from Applied Biosystems; Thermo Fisher Scientific, Inc.). Each gene reaction was performed in duplicates and all transcript values were normalized to GAPDH. The Cq values for each gene was generated using the \( \Delta\Delta \text{Cq} \) method. The values were first normalized to GAPDH. Then to generate the final folds, the values were renormalized to the non-neoplastic samples.

**Microscopy, semiquantitative scoring system and statistical analysis.** All images were obtained using an EVOS Imaging System (Invitrogen; Thermo Fisher Scientific, Inc.). In the present analysis for IHC, 5/7 tumor tissues were compared to non-neoplastic tissue from the same patient. The immunoreactive score (IRS) was utilized to evaluate each immunohistochemical stain and performed by a single pathologist (JP) (37). Histologic evaluation included the percentage of positive cells in the lesional and non-lesional areas and the staining intensity. IRS was a product of multiplication between the positive-cell proportion score (0-4) and staining intensity score (0-3). The final score was interpreted as negative (0-1), mild (2-3), moderate (4-8) or strongly positive (9-12). A detailed calculation for generating the IRS is illustrated in Table SI. Mann-Whitney test was performed to compare the median data values between non-neoplastic and neoplastic cells. The non-parametric two-sided Mann-Whitney test was conducted using Graphpad Prism 7 software for all statistical analyses and a P-value <0.05 was considered statistically significant.

**Results**

**Patient characteristics and histopathology.** All patients in the present study, were male and the median age of the patients in the present study was 13 years. Previous studies have reported that FL-HCC occurs predominantly in females (2), however, others have reported that both males and females are equally likely to be affected (38,39). Two patients (P3 and P6) presented to our institution with metastatic disease. Patient P6 had prior liver resection at an outside institution and presented with recurrent metastatic disease and underwent tumor biopsy. The median follow-up for the entire cohort was 26 months (range 16-70 months). All patients except P7 had undergone neo-adjuvant therapy prior to surgery. Patient demographics, tumor data, and clinical course is summarized in Table I.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yrs)</th>
<th>Gender</th>
<th>Length of Survival (mo)</th>
<th>Prior Liver Resection</th>
<th>Tumor Size (cm)</th>
<th>Metastatic Disease</th>
<th>Neo-Adjuvant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>50</td>
<td>M</td>
<td>32</td>
<td>No</td>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P2</td>
<td>60</td>
<td>M</td>
<td>42</td>
<td>Yes</td>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P3</td>
<td>45</td>
<td>F</td>
<td>60</td>
<td>Yes</td>
<td>8</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P4</td>
<td>55</td>
<td>M</td>
<td>36</td>
<td>Yes</td>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P5</td>
<td>65</td>
<td>M</td>
<td>24</td>
<td>No</td>
<td>7</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>P6</td>
<td>58</td>
<td>M</td>
<td>28</td>
<td>Yes</td>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P7</td>
<td>42</td>
<td>M</td>
<td>60</td>
<td>No</td>
<td>5</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

**p53 protein expression is increased in FL-HCC.** The expression of p53 and its activated form, phosphorylated p53 (p-p53) in tumor tissue was then determined. Western blot analysis was performed from whole cell protein lysates using p53 and p-p53 (serine 15) antibodies and the corresponding protein levels were assessed. Quantitative analysis of the immunoblots revealed that p53 protein was significantly increased in tumor tissues compared to matching non-neoplastic liver tissues (Mann-Whitney test, P=0.03, Fig. 2A and B). As revealed in Fig. 2C, individual immunoblot quantification demonstrated that p53 was increased in 5/6 tumor samples. Furthermore, western blot analysis revealed that although the overall p-p53 expression was not significantly elevated (Mann-Whitney test, P=0.39), there was an increase in p-p53 in 4/6 tumors (Fig. 2D-F).

Next, the subcellular localization pattern of p53 and p-p53 was assessed. IHC was performed on paraffin-embedded sections using anti-p53 and anti-p-p53 antibodies followed by nuclear and cytoplasmic assessment of each protein using the IRS quantification system. There was very low nuclear and cytoplasmic p53 staining in both tumor and normal liver tissue (Fig. S1). In contrast, p-p53 was detected in both the

**PRKACA-DNAJB1 fusion protein is expressed in the majority of FL-HCC.** A recent study described the presence of PRKACA-DNAJB1 fusion gene in chromosome 19 in FL-HCC tumors (40). This fusion gene results from a chromosomal deletion of 400 kilobase pairs, which generates a fusion chimera between exon 1 of DNAJB1 (Heat Shock Protein 40) and exons 2 through 10 of the catalytic subunit of protein kinase A, PRKACA (40,41). Using western blot analysis, the presence of PRKACA-DNAJB1 fusion protein with an antibody targeting the c-terminus of PRKACA was assessed. It was revealed that 6/7 tumor samples expressed the fusion protein (Fig. 1). The native PRKACA band was detected at ~41 kDa and the band shift at ~46 kDa in the immunoblots represented the presence of the fusion protein. Tumor sample from patient P4 was confirmed as FL-HCC histologically, however, the fusion protein was not present in this tumor.
Table I. Patient and tumor characteristics.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at diagnosis</th>
<th>Sex</th>
<th>BMI (kg/m²)</th>
<th>AFP (ng/ml)</th>
<th>Tumor size (cm)</th>
<th>Extent of tumor</th>
<th>Surgery</th>
<th>Clinical course</th>
<th>Date of recruitment</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>13.7</td>
<td>M</td>
<td>19.6</td>
<td>1.1</td>
<td>19.5x13.4x8.5</td>
<td>Liver segments II/III, IVa/IVb; tumor thrombus in PV, HV, IVC and RA</td>
<td>Total hepatectomy on cardiopulmonary bypass; ex vivo left hepatectomy; right lobe autotransplantation</td>
<td>Underwent resection of brain metastasis at 19 months post-liver resection; alive at 75-month follow-up</td>
<td>02/26/2013</td>
</tr>
<tr>
<td>P2</td>
<td>13.6</td>
<td>M</td>
<td>14.4</td>
<td>1</td>
<td>9x8x6.5</td>
<td>Liver left lobe; 1.1 cm lesion in right lobe; tumor thrombus in PV, SV, SMV</td>
<td>Multivisceral transplant (liver, intestine, pancreas, spleen, stomach)</td>
<td>Alive at 77-month follow-up after transplant with no evidence of disease</td>
<td>07/16/2013</td>
</tr>
<tr>
<td>P3</td>
<td>13.4</td>
<td>M</td>
<td>16.5</td>
<td>32897</td>
<td>14.1x12x7.5</td>
<td>Liver right lobe; hepatic vein</td>
<td>Right trisegmentectomy</td>
<td>Alive at 55 months with metastatic disease</td>
<td>11/06/2014</td>
</tr>
<tr>
<td>P4</td>
<td>11.4</td>
<td>M</td>
<td>14.1</td>
<td>5</td>
<td>8.6x6.1x6.0</td>
<td>Liver segments II/IVa</td>
<td>Left hepatectomy</td>
<td>Recurrence at 108 days; died of recurrence 26 months after initial diagnosis</td>
<td>10/27/2014</td>
</tr>
<tr>
<td>P5</td>
<td>15.8</td>
<td>M</td>
<td>31.3</td>
<td>148</td>
<td>18.5x9x8</td>
<td>Right lobe; portal vein invasion</td>
<td>Right trisegmentectomy</td>
<td>Recurrence at 9 months; salvage transplant at 23 months; alive with recurrence at 45 months after initial diagnosis</td>
<td>09/12/2015</td>
</tr>
<tr>
<td>P6</td>
<td>10.8</td>
<td>M</td>
<td>N/A</td>
<td>4</td>
<td>10.0x6.8x5.5</td>
<td>Caudate lobe recurrence; involvement of PV; HA; and CBD</td>
<td>Attempted resection; core needle biopsy</td>
<td>Recurrence at 64 months; died 87 months after initial diagnosis</td>
<td>09/22/2016</td>
</tr>
<tr>
<td>P7</td>
<td>14</td>
<td>M</td>
<td>16</td>
<td>14</td>
<td>10.8x2.3x8.3</td>
<td>Liver segments II/III/IV, invasion of CBD</td>
<td>Liver transplant</td>
<td>Recurrence at 279 days after transplant; alive at 15 months post-transplant</td>
<td>12/22/2017</td>
</tr>
</tbody>
</table>

*All tissue samples were obtained at Boston Children's Hospital. PV, portal vein; HV, hepatic vein; IVC, inferior vena cava; RA, right atrium; SV, splenic vein; SMV, superior mesenteric vein; HA, hepatic artery; CBD, common bile duct.*
nucleus and cytoplasm of tumor cells with no overall significant differences between tumor cells and non-neoplastic cells (P=0.28 for nuclear p-p53 and P=0.14 for cytoplasmic p-p53; Mann-Whitney test, Fig. 3A-C). However, the majority of the patients had higher IRS values for cytoplasmic p-p53 in the tumor cells compared to the non-neoplastic cells.

ATM, a p53 regulator, is activated in FL-HCC. Next, the expression and localization of ATM protein kinase, a known upstream regulator of p53, was examined (42). The detection of ATM and phosphorylated-ATM (serine 1981; p-ATM) protein levels was not feasible due to unsuitable antibodies for western blotting. However, protein expression and localization of ATM and p-ATM in tumors cells and non-neoplastic cells were examined using IHC (Fig. 3D and G) and IRS values were generated for nuclear and cytoplasmic localization of total ATM and p-ATM proteins (Fig. 3E and F and H and I, respectively). There was no statistically significant difference in nuclear or cytoplasmic ATM expression between tumor cells and non-neoplastic cells (P=0.20 for nuclear ATM and P=0.16 for cytoplasmic ATM; Mann-Whitney test). However, there was a significant increase in p-ATM levels in the nuclei of tumors compared to normal cells (Mann-Whitney test, P=0.005, Fig. 3H).

MDM4 transcript levels are increased in the majority of FL-HCC tumors. Previous studies have reported that MDM4 inhibits the tumor suppressor activity of p53 by binding to its N-terminus (22,23) and increased expression of MDM4 has been reported in several other cancer types (25,28,34,35,43-45). The present quantitative RT-PCR results indicated that the relative transcript levels of MDM4 were increased in 4/7 tumors (Fig. 4A). However, when all samples were analyzed together, a statistically significant increase in MDM4 transcript levels in FL-HCC tumors compared to their non-neoplastic liver tissue (Mann-Whitney test, P=0.69, Fig. 4B) was not observed. This finding indicated that MDM4 gene expression is increased in a proportion of FL-HCC tumors.
**MDM4** nuclear localization is significantly increased in FL-HCC. Given the increased **MDM4** transcript levels in the majority of tumor samples, **MDM4** protein expression was assessed. Western blot analysis revealed an increase in **MDM4** protein levels in 4/6 tumor samples compared to the non-neoplastic liver (Fig. 5A and C) but it did not reach statistical significance when the samples were analyzed together (Mann-Whitney test, P=0.93, Fig. 5B). However, there was a significant increase in nuclear
MDM4 in tumor cells compared to non-neoplastic cells as revealed by IHC (Mann-Whitney test, P=0.009; Fig. 5D and E).

Discussion

In the present study, the DDR pathway components p53, ATM, and MDM4 were examined in FL-HCC. The present findings indicated that the DDR pathway may be activated given the increase in nuclear p-ATM in FL-HCC. p53, the downstream target of ATM, was also increased in tumor tissues without any difference in its subcellular localization as assessed by IHC. In addition, the activated or phosphorylated form of p53 (p-p53) did not localize to the nucleus as predicted; instead p-p53 was localized to the cytoplasmic compartment in tumor samples. Moreover, the transcript levels of MDM4, a negative regulator of p53, were increased in 4/7 tumors, however, protein nuclear localization was increased in all tumor samples (Table II).

FL-HCC was specifically focused on for the following reasons: i) FL-HCC does not commonly arise in a background of liver disease; ii) FL-HCC has a distinct histopathology compared to conventional HCC; and iii) unlike many conventional HCC types, FL-HCC does not contain multiple gene mutations, thereby representing a potentially homogeneous tumor type. A recent advance has been the revelation of a 400-kilobase pair deletion in chromosome 19 resulting in DNJAB1-PRKACA fusion transcript and protein in the majority of FL-HCC tumors (40,41). A recent study using a mouse model demonstrated that expression of the fusion protein in the liver is sufficient to result in FL-HCC, thus demonstrating its role as an oncogenic driver (46). In the present study, the presence of this fusion protein was confirmed in 6/7 of the tumor samples examined. Given that our cohort only had a single tumor that did not express the fusion protein, a conclusive determination was not feasible without a larger sample size. This highlights the major limitations of conducting cancer research on rare tumors such as FL-HCC which include: i) Small sample size; ii) limited amount of patient-derived tumor tissue; and iii) lack of in vitro or in vivo models.

p53 is one of the key components of the DDR pathway and its transcriptional activity has been revealed to prevent aberrant oncogenic cell growth. Studies have reported that p53 is mutated in ~50% of lung, liver, breast, brain, and prostate cancers (24,47-49). However, mutations in p53 have not been commonly observed in FL-HCC (40,50). Upon detection of cellular stress and DNA damage, ATM is activated which subsequently activates p53 to induce downstream target genes to repair DNA damage, halt cell growth, or induce apoptosis (51-54). In fact, in the FL-HCC tumor tissue there was...
samples assessed in the present study lacked nuclear p-p53 as the increased phosphorylated ATM in the nucleus, the tumor transcriptional and tumor suppressor activity. However, despite phosphorylated p53 localizes to the nucleus where it performs its these tumors. Under normal conditions, activated p53 or phosphorylated ATM which is an upstream regulator of p53 via translocation to the cytoplasm in several cancers (55-57). Notably, cancers lacking nuclear p53 are not responsive to chemotherapy or radiotherapy similar to FL-HCC tumor cells as opposed to the nucleus. These findings confirmed previously published studies, which demonstrated a loss of tumor suppressive function of non-mutant p53 via translocation to the cytoplasm in several cancers (55-57). Notably, cancers lacking nuclear p53 are not responsive to conventional chemotherapy or radiotherapy similar to FL-HCC (55,56,58,59).

In the present study, the tumors demonstrated activation of ATM which is an upstream regulator of p53. ATM activation may be due to i) tumor cell DNA instability and attempt at DNA repair or apoptosis or ii) a result of the toxic effects of neo-adjuvant chemotherapy (60). In either case, the expected response of p53 to elicit DNA damage repair or apoptosis was not observed. Clinically, it is clear that FL-HCC tumors are not responsive to conventional chemotherapy which was also evident in our cohort given the high rate of tumor progression and recurrence. On the other hand, assuming that ATM activation is a result of the cell's recognition of DNA instability following malignant transformation, the normal function of p53 is still compromised. In our tumor cohort a significant nuclear increase in the p53 negative regulator, MDM4, was observed. Therefore, it is possible that increased MDM4 results in inhibition of the normal function of p53 in these tumors. The exact mechanism for increased MDM4 expression and nuclear localization is unclear, although potential mechanisms may include increased gene expression; decreased protein degradation due to changes in post-transcriptional regulation; or alteration in post-translational regulation of MDM4. For example, recent studies have demonstrated that levels of miRNA-128 and miRNA-370 are decreased in pancreatic and colon cancer, respectively (61,62). These studies demonstrated that the aforementioned miRNAs can directly inhibit MDM4 and promote cancer cell apoptosis. The role of miRNAs in the regulation of MDM4 in FL-HCC is unknown at this time and requires further research by examining the differential expression of known MDM4-specific miRNA in tumor cells compared to normal hepatocytes.

In the cancers which do not have mutated p53, there is evidence that tumor cells inhibit the normal function of p53 and prevent the cell from committing to DNA repair or apoptosis. Even in tumors with p53 mutation, studies have focused on re-establishing the normal function of p53 despite the presence of its mutated form. For example, in vitro studies have revealed that small molecules can reverse the aberrant function of mutant p53 and subsequently induce apoptosis (63-65). Therefore, the idea of reactivating or restoring the function of p53 for the treatment of cancer has been gaining interest (12,66). One strategy to restore the normal function of non-mutated p53 is to target its negative regulators such as MDM4. MDM4 induces its inhibitory effect by binding to the N-terminus transactivation domain of p53 and affecting its transcriptional activity (22,23,67). Recent studies have revealed that MDM4 is frequently overexpressed in a number of cancer types lacking p53 mutations including breast, melanoma, retinoblastoma, acute myeloid leukemia, and esophageal squamous cell carcinoma (25,28,43,45,68,69). Therefore, in these cancers, inhibition of MDM4 activity has been an appealing therapeutic strategy to reactivate the function of p53 and ultimately control aberrant cell proliferation and tumor progression. In light of these findings, there is an interest in identifying small molecules or peptides that specifically target MDM4. In fact, MDM4 inhibitors have exhibited promising efficacy in both in vitro and in vivo models of cancers. Wang et al demonstrated that the MDM4 inhibitor, NSC207895, restored normal function of p53 in breast cancer cell lines and triggered cell apoptosis (70). Likewise, knockdown of MDM4 in breast cancer cell lines and xenograft models was revealed to induce senescence of cancer cells (29). In addition, in retinoblastoma cells, MDM4 inhibitor, SJ-172550, effectively triggered cell death (71). Lastly, in melanoma cells, known to be resistant to BRAF (B-Raf proto oncogene, serine threonine kinase) inhibitors, the inhibition of p53-MDM4 interaction using the MDM4 inhibitor, SAH-p53-8, exhibited effective activation of p53 and reduction in cell growth (28). Collectively, these studies indicated that inhibiting MDM4 can restore p53 activity in

### Table II. Summary of tumor IHC and MDM4 transcript levels.

<table>
<thead>
<tr>
<th>Patient</th>
<th>DNAJB1-PRKACA fusion present</th>
<th>MDM4 transcript levels</th>
<th>MDM4</th>
<th>Nuclear p-ATM</th>
<th>Cytoplasmic p-ATM</th>
<th>Nuclear p-p53</th>
<th>Cytoplasmic p-p53</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Yes</td>
<td>0.34</td>
<td>+++</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td>P2</td>
<td>Yes</td>
<td>0.41</td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P3</td>
<td>Yes</td>
<td>10.26</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>P4</td>
<td>No</td>
<td>119.25</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>P5</td>
<td>Yes</td>
<td>17.18</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P6</td>
<td>Yes</td>
<td>0.00006</td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>P7</td>
<td>Yes</td>
<td>8.01</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

IHC IRS score: 0-1 (-); 2-3 (+); 4-8 (++); 9-12 (+++). IHC, immunohistochemistry; MDM4, mouse double minute 4; IRS, immunoreactive score; p-p53, phosphorylated p53; p-ATM, phosphorylated ATM.
cancers lacking p53 mutations, thereby providing a promising new therapeutic strategy. To the best of our knowledge, the present study is the first to specifically examine MDM4 in FL-HCC. Whether p53 dysregulation is directly due to MDM4 activity in this tumor type is yet unclear, however, given the existing evidence in other cancers, it is a plausible hypothesis. In conclusion, our finding of increased nuclear MDM4 in FL-HCC tumors unveils a potential new target for the development of novel treatments for this highly lethal cancer.

Acknowledgements

We would like to thank Dr Amanda Dios, Kaly Mueller, Eric Granucci, Dr Ina Kycia, Dr Sanjeev Vasudevan and Dr Sarah Woodfield for their scientific advice on this study.

Funding

The present research was funded by CHMC Surgical Foundation, Inc.

Author contributions

AK and KV designed and AK performed all experiments. JP and ARPA reviewed the pathology slides and quantified the staining sections. AK, MJL, SSK, GSV and KV analyzed all data. AK and KV wrote the manuscript and all co-authors reviewed the final manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital. The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital. The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital. The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital. The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital. The use of human tissue in the present study was approved by the Institutional Review Board at Boston Children’s Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors do not have any personal, professional, or financial relationships that would constitute a competing interest in regards to this work.

References


